Structural Polymorphism of Sorafenib Tosylate as a Key Factor in Its Solubility Differentiation

The presence of active pharmaceutical ingredients (APIs) in the forms of different polymorphic states can induce differences in their physicochemical properties. In the case of poorly soluble APIs, like the oncological drug sorafenib tosylate, small variations in solubility may result in large bioav...

Full description

Bibliographic Details
Main Authors: Gabriela Wiergowska, Anna Stasiłowicz, Andrzej Miklaszewski, Kornelia Lewandowska, Judyta Cielecka-Piontek
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/13/3/384